June 23, 2014

The National Advertising Division last week determined that Westport Pharmaceuticals, maker of Zephrex-D nasal decongestant tablets, can support the claims challenged before NAD by Acura Pharmaceuticals, the maker of Nexafed, a competing product.

November 5, 2013

Acura Pharmaceuticals on Monday announced that Nexafed, its next generation pseudoephedrine with abuse-deterrent technology, will now be stocked by Rite Aid.

September 5, 2013

Acura Pharmaceuticals announced a study, published in the September issue of the American Journal of Drug and Alcohol Abuse, that validates the ability of Nexafed to uniquely disrupt the extraction and conversion of pseudoephedrine into methamphetamine.

July 15, 2013

Acura Pharmaceuticals on Monday announced a second-generation prototype formulation of its methamphetamine-resistant IMPEDE technology with pseudoephedrine hydrochloride yielded no measurable amount of methamphetamine hydrochloride when processed in the direct conversion or one-pot method.

March 6, 2013

Acura Pharmaceuticals announced that its next-generation pseudoephedrine with abuse-deterrent technology will now be stocked by North Carolina's Kerr Drug.

December 27, 2012

In support of its December launch of the pseudoehedrine product Nexafed, Acura Pharmaceuticals recently kicked off a national e-mail campaign to help drive pharmacists to the Nexafed website with content specifically designed for the pharmacist audience, including infographics, graphic representations of study data and a behind-the-scenes look at Nexafed's abuse-deterrent technology.

November 15, 2012

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

November 8, 2012

Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that in inhibits the diversion to methamphetamnine.

October 29, 2012

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

January 24, 2012

A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.